Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With FDA Questions Answered, Edwards Expects Sapien Approval “Any Day”

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences expects FDA approval of its Sapien transcatheter aortic heart valve replacement “any day,” CEO Michael Mussallem said Oct. 19.

You may also be interested in...

Edwards Wins Approval For Sapien Just In Time For TCT

Sapien Stroke Discussion Continues With Expanded PARTNER Analysis

Investigators from Edwards Lifesciences’ PARTNER clinical trial reported a more detailed analysis of the incidence of stroke in study patients treated with the firm's Sapien transcatheter valve, though there did not appear to be any major new revelations that would impact approvability.

FDA Holds Up Edwards-DexCom Continuous Glucose Monitor For Hospital Use

Edwards Lifesciences' and DexComs’ first-of-its-kind continuous glucose monitor for hospital use is running into delays at FDA.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts